Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by FarmerBettyon Jun 05, 2022 11:17am
250 Views
Post# 34732451

RE:RE:RE:RE:RE:RE:RE:The Big IF

RE:RE:RE:RE:RE:RE:RE:The Big IFA couple of reasons for being hesitant look at the example below which investors pickup on. Nearing to completion to 9 months later kicking the can down the road, Eugene describing it as rapid progress. 
Don't need the Nasdaq need credibility with credible news. Eugene, Elliott the consultant and the Boston group?


For the three months ended Sep 30,2021
"Development of assays to measure drug levels in both nonhuman primate and human studies have been initiated and are nearing completion."

For the year ended Dec 31, 20121
"Development of assays to measure drug levels in both nonhuman primate and human studies have been initiated and are expected to complete development in the second quarter of 2022"

For the three months ended Mar 31,2021
"Development of assays to measure drug levels in nonhuman primates was completed in the second quarter and development of assays to measure drug levels in human studies are expected to be completed in the third quarter of 2022"
<< Previous
Bullboard Posts
Next >>